Francisco Alvarez-Lerma

Summary

Affiliation: Hospital del Mar
Country: Spain

Publications

  1. ncbi Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia
    F Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    J Chemother 13:70-81. 2001
  2. ncbi [Effectiveness of contact isolation in the control of multiresistant bacteria in an intensive care service]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Universidad Autonoma de Barcelona, Spain
    Enferm Infecc Microbiol Clin 20:57-63. 2002
  3. ncbi Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients
    F Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital Universitari del Mar, Barcelona, Spain
    J Chemother 17:417-27. 2005
  4. ncbi Levofloxacin in the treatment of ventilator-associated pneumonia
    F Alvarez-Lerma
    Service of Intensive Care Medicine, Hospital del Mar, Universitat Autonoma de Barcelona, Spain
    Clin Microbiol Infect 12:81-92. 2006
  5. ncbi Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study
    F Alvarez-Lerma
    Hospital Universitari del Mar, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Chemother 21:330-7. 2009
  6. ncbi Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain
    Jordi Rello
    Critical Care Department, Joan XXIII University Hospital, CIBERes Enfermedades Respiratorias, IISPV, Mallafre Guasch 4, 43007 Tarragona, Spain
    Crit Care 13:R148. 2009
  7. ncbi [Risk and prognostic factors of Pseudomonas aeruginosa bacteremia in critically ill patients]
    F Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital Universitario del Mar, Barcelona, Spain
    Med Clin (Barc) 117:721-6. 2001
  8. ncbi [Levofloxacin in the treatment of nosocomial infection in critically ill patients]
    F Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona
    Rev Esp Quimioter 21:83-92. 2008
  9. ncbi [Observational study investigating the use of levofloxacin in ICU patients]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    Enferm Infecc Microbiol Clin 22:220-6. 2004
  10. ncbi [Levofloxacin in patients in the ICU. Factors influencing the choice of dose and its use in combined therapy]
    F Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    Rev Esp Quimioter 17:57-63. 2004

Detail Information

Publications73

  1. ncbi Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia
    F Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    J Chemother 13:70-81. 2001
    ..3%) in the ceftazidime/amikacin group. The results of this study confirm that monotherapy with meropenem is well tolerated and provides superior efficacy to the conventional combination of ceftazidime and amikacin in combating VAP...
  2. ncbi [Effectiveness of contact isolation in the control of multiresistant bacteria in an intensive care service]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Universidad Autonoma de Barcelona, Spain
    Enferm Infecc Microbiol Clin 20:57-63. 2002
    ....
  3. ncbi Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients
    F Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital Universitari del Mar, Barcelona, Spain
    J Chemother 17:417-27. 2005
    ..In conclusion, in critically ill patients admitted to the ICU, the use of voriconazole was affective in 50% of cases. The drug was well tolerated and discontinuation of voriconazole treatment due to adverse events was not necessary...
  4. ncbi Levofloxacin in the treatment of ventilator-associated pneumonia
    F Alvarez-Lerma
    Service of Intensive Care Medicine, Hospital del Mar, Universitat Autonoma de Barcelona, Spain
    Clin Microbiol Infect 12:81-92. 2006
    ..The availability of the oral formulation allows sequential therapy, switching from the intravenous route to the oral route. Levofloxacin is well tolerated by critically ill patients, with few adverse events of mild to moderate severity...
  5. ncbi Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study
    F Alvarez-Lerma
    Hospital Universitari del Mar, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Chemother 21:330-7. 2009
    ..The use of liposomal amphotericin B both as first line and rescue treatment and mainly for proven invasive fungal infection was associated with a high rate of satisfactory clinical response...
  6. ncbi Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain
    Jordi Rello
    Critical Care Department, Joan XXIII University Hospital, CIBERes Enfermedades Respiratorias, IISPV, Mallafre Guasch 4, 43007 Tarragona, Spain
    Crit Care 13:R148. 2009
    ..We describe the clinical and epidemiologic characteristics of the first 32 persons reported to be admitted to the intensive care unit (ICU) due to influenza A (H1N1)v infection in Spain...
  7. ncbi [Risk and prognostic factors of Pseudomonas aeruginosa bacteremia in critically ill patients]
    F Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital Universitario del Mar, Barcelona, Spain
    Med Clin (Barc) 117:721-6. 2001
    ..To determine risk and prognostic factors in patients admitted to the intensive care unit (ICU) in which an episode of bacteremia caused by Pseudomonas aeruginosa has been diagnosed...
  8. ncbi [Levofloxacin in the treatment of nosocomial infection in critically ill patients]
    F Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona
    Rev Esp Quimioter 21:83-92. 2008
    ..Their use in community-acquired infections has been widely documented, while it is less frequent and known in nosocomial infections (NI)...
  9. ncbi [Observational study investigating the use of levofloxacin in ICU patients]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    Enferm Infecc Microbiol Clin 22:220-6. 2004
    ..There is little information on the use of levofloxacin, a new quinolone, in ICU patients...
  10. ncbi [Levofloxacin in patients in the ICU. Factors influencing the choice of dose and its use in combined therapy]
    F Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    Rev Esp Quimioter 17:57-63. 2004
    ..The selection of combined therapy was associated with a worse prognosis...
  11. ncbi [Indications for antifungal treatment in intensive care unit patients]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    Enferm Infecc Microbiol Clin 22:279-85. 2004
    ..This study investigates the indications for antifungal treatment in patients admitted to intensive care units (ICUs) in Spain and determines the frequency at which each individual drug is prescribed...
  12. ncbi Clinical experience with levofloxacin in the treatment of pneumonia in ICU patients
    F Alvarez Lerma
    Intensive Care Unit, Hospital del Mar, Barcelona, Spain
    J Chemother 16:15-7. 2004
  13. ncbi [Identification of risk times for dissemination of methicillin-resistant Staphylococcus aureus in an intensive care unit]
    Francisco Alvarez-Lerma
    Universidad Autonoma de Barcelona, UDUM, Barcelona, Spain
    Med Clin (Barc) 123:207-10. 2004
    ..The objective of this study was to identify the risk intervals for the spread of MRSA in ICU patients and to assess the relationship between these periods and the development of new cases of MRSA acquired in the ICU...
  14. ncbi [Staphylococcus aureus nosocomial infections in critically ill patients admitted in intensive care units]
    Francisco Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Espana
    Med Clin (Barc) 126:641-6. 2006
    ....
  15. ncbi Levofloxacin in the treatment of pneumonia in intensive care unit patients
    F Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    J Chemother 16:549-56. 2004
    ..07; 95% CI 1.23-7.65), septic shock (OR 3.49; 95% CI 1.30-9.39), or therapeutic failure (OR 32.6; 95% CI 13.5-78.9). A total of 15% of the patients experienced adverse effects possibly or probably related the antibiotic given...
  16. ncbi [Infections caused by Acinetobacter spp. in critically ill ICU patients]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    Enferm Infecc Microbiol Clin 23:533-9. 2005
    ..To determine the frequency of infections caused by Acinetobacter spp. in critically ill patients admitted to Spanish intensive care units (ICUs) and to assess the clinical features and outcome...
  17. ncbi [Monitoring plasma antibiotic concentrations in Spanish hospitals]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    Enferm Infecc Microbiol Clin 24:14-9. 2006
    ..Monitoring of plasma aminoglycoside and vancomycin concentrations is a measure of good clinical practice in critically ill patients. However, the frequency and application of this practice in Spanish hospitals is unknown...
  18. ncbi Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    Crit Care 10:R78. 2006
    ....
  19. ncbi [Antibiotic policy in critical patients]
    F Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Espana
    Med Intensiva 34:600-8. 2010
    ....
  20. ncbi [Enterococcal infections in critically ill patients admitted to ICU]
    Francisco Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Espana
    Med Clin (Barc) 121:281-6. 2003
    ..To determine the frequency of infections caused by Enterococcus spp. in critically ill patients admitted to ICUs in Spain and to describe the clinical features and outcome of those patients in whom this pathogen was isolated...
  21. ncbi [Fungal colonization and/or infection in intensive care units. Multicenter study of 1,562 patients]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva Hospital del Mar Barcelona España
    Med Clin (Barc) 121:161-6. 2003
    ....
  22. ncbi [Recommendations for antibiotic monitoring in ICU patients]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:230-9. 2008
    ....
  23. ncbi Moisturizing body milk as a reservoir of Burkholderia cepacia: outbreak of nosocomial infection in a multidisciplinary intensive care unit
    Francisco Alvarez-Lerma
    Service of Intensive Care Medicine, Hospital Universitari del Mar, Universitat Autonoma de Barcelona, Passeig Maritim 25 29, E 08003 Barcelona, Spain
    Crit Care 12:R10. 2008
    ..An outbreak of severe nosocomial Burkholderia cepacia infections in patients admitted to intensive care unit (ICU), including investigation of the reservoir, is described...
  24. ncbi [Recommendations for antibiotic monitoring in ICU patients]
    Francisco Alvarez
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Espana
    Farm Hosp 32:113-23. 2008
    ....
  25. ncbi [Rescue therapy for serious infections in hospitalized patients]
    F Alvarez Lerma
    Servicio de Medicina Intensiva y Servicio de Farmacia, Hospital Universitario del Mar, Barcelona, Spain
    Rev Esp Quimioter 20:234-40. 2007
  26. ncbi [Role of voriconazole in critically ill patients with invasive mycoses]
    Francisco Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital Universitario del Mar, Barcelona, Spain
    Rev Iberoam Micol 24:209-12. 2007
    ..v. formulation) and history of azoles use should be considered, although none of these circumstances is an absolute contraindication for the prescription of voriconazole in critically ill patients...
  27. ncbi Characteristics of doripenem: a new broad-spectrum antibiotic
    Francisco Alvarez-Lerma
    Intensive Care Unit, Pharmacy Department, Hospital del Mar, Passeig Maritim 25 29, Barcelona, Spain
    Drug Des Devel Ther 3:173-90. 2009
    ..The European Medicines Agency has approved the use of doripenem for the same indications in addition to nosocomial pneumonia regardless of whether it is ventilator-associated or not...
  28. ncbi [Treatment approach for fungal infections in critically ill patients admitted to intensive care units: results of a multicenter survey]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva Hospital Universitario del Mar Barcelona Spain
    Enferm Infecc Microbiol Clin 21:83-8. 2003
    ..infections. Among other results, clinical scenarios in which early prescription of antifungal agents is indicated were identified...
  29. ncbi [Epidemiology of the primary and vascular catheter-related bacteriemias in critical patients admitted to an Intensive Medicine Department]
    F Alvarez Lerma
    Hospital del Mar, Barcelona, Espana
    Med Intensiva 34:437-45. 2010
    ..This article analyzes the evolution of the rates, etiologies and markers of multiresistance of the most common pathogens in the BVC (including the primary bacteriemias) in the Spanish Intensive Medicine Departments (ICU)...
  30. ncbi [Differences in the use of tigecycline between ICU patients and non-ICU patients]
    F Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    Rev Esp Quimioter 23:63-71. 2010
    ..Tigecycline is a new broad spectrum antibiotic that is predominantly used for the treatment of severe infections both in critically ill patients admitted to the ICU and in non-ICU patients with less severe clinical conditions...
  31. ncbi Candiduria in critically ill patients admitted to intensive care medical units
    Francisco Alvarez-Lerma
    Department of Intensive Care Medicine, Hospital Universitari del Mar, Paseo Maritimo 25 29, 08003, Barcelona, Spain
    Intensive Care Med 29:1069-76. 2003
    ....
  32. ncbi [National Study of Control of Nosocomial Infection in Intensive Care Units. Evolutive report of the years 2003-2005]
    F Alvarez-Lerma
    Hospital Universitario del Mar, Barcelona, Espana
    Med Intensiva 31:6-17. 2007
    ..Describe the national rates of acquired invasive device-related infections in the ICU during 2003, 2004 and 2005, their etiology and evolution of the multiresistance markers...
  33. ncbi Gram-positive cocci infections in intensive care: guide to antibacterial selection
    Francisco Alvarez-Lerma
    Intensive Care Medicine Service, Hospital del Mar, , Barcelona, Spain
    Drugs 66:751-68. 2006
    ....
  34. ncbi Risk factors for candidaemia in critically ill patients: a prospective surveillance study
    Ricard Jordà-Marcos
    Department of Intensive Care Medicine, Hospital Son Dureta and Clínica Rotger, Palma de Mallorca, Spain
    Mycoses 50:302-10. 2007
    ..albicans. Risk factors for candidaemia identified included Candida colonisation, elective surgery, total parenteral nutrition and haemodialysis...
  35. ncbi [Impact of primary and intravascular catheter-related bacteremia due to coagulase-negative staphylococci in critically ill patients]
    P M Olaechea
    Servicio de Medicina Intensiva, Hospital de Galdakao Usansolo, Vizcaya, Espana
    Med Intensiva 35:217-25. 2011
    ..To study the impact of coagulase-negative staphylococcal (CNS) primary and intravascular catheter-related bloodstream infection (PBSI/CRBSI) on mortality and morbidity in critically-ill patients...
  36. ncbi Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome
    Jose Garnacho-Montero
    Department of Intensive Care Medicine, Hospital Universitario Virgen del Rocio, Sevilla, Spain
    Crit Care 9:R191-9. 2005
    ..were isolated from respiratory secretions, using a database from a study designed to assess fungal infections...
  37. ncbi A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization
    Cristóbal León
    Intensive Care Unit, Hospital Universitario de Valme, Universidad de Sevilla, Sevilla, Spain
    Crit Care Med 34:730-7. 2006
    ..To obtain a score for deciding early antifungal treatment when candidal infection is suspected in nonneutropenic critically ill patients...
  38. ncbi Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial
    Cristóbal León
    Intensive Care Unit, Hospital Universitario de Valme, Universidad de Sevilla, Carretera de Cádiz s n, 41014 Sevilla, Spain
    Intensive Care Med 30:1891-9. 2004
    ..To determine the efficacy of minocycline and rifampin-impregnated catheters compared to non-impregnated catheters in critically ill patients...
  39. ncbi Use of linezolid in critically ill patients admitted to intensive care units
    O Rodriguez
    Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain
    Rev Esp Quimioter 22:68-75. 2009
    ..This antibiotic has acted as a good therapeutic resource against clinical failure in infections treated with glycopeptides...
  40. ncbi Severe 2009 A/H1N1v influenza in pregnant women in Spain
    Enrique Maravi-Poma
    Intensive Care Unit, Hospital Virgen del Camino, Pamplona, Spain
    Crit Care Med 39:945-51. 2011
    ..To describe the severity of the 2009 influenza A/H1N1v illness among pregnant women admitted to Spanish intensive care units...
  41. ncbi Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function
    F Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital Universitari de Mar, Autonomous University of Barcelona, Spain
    J Chemother 20:93-100. 2008
    ..v. voriconazole (60% size=1>vs. 75%, P = 0.385). The use of i.v. voriconazole in ICU patients with pretreatment impaired renal function was not associated with renal or liver damage nor with an increase in ICU mortality...
  42. ncbi [Candiduria in patients with urethral catheter admitted in Intensive Care Unit. Etiology and in vitro susceptibility to fluconazole]
    Yolanda Morera
    IMIM IMAS, Universitat Autonoma de Barcelona, Spain
    Med Clin (Barc) 118:580-2. 2002
    ..The etiological mechanisms and the appropriateness of administering an antifungal treatment in these patients is controversial...
  43. ncbi [Daptomycin for the treatment of Gram-positive microorganisms in the critically-ill patient]
    Francisco Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Parc Salut Mar, Barcelona, Espana
    Med Clin (Barc) 135:29-35. 2010
    ..In the last few years, treatment of these infections has changed due to better knowledge of the limitations of glycopeptides and the introduction of novel antimicrobials, such as daptomycin...
  44. ncbi Factors related to hospital stay among patients with nosocomial infection acquired in the intensive care unit
    Pedro M Olaechea
    Intensive Care Unit, Hospital de Galdakao, Bizkaia, Spain
    Infect Control Hosp Epidemiol 24:207-13. 2003
    ..CONCLUSIONS: The presence of nosocomial infection and the number of infection episodes were the variables with the strongest association with prolonged hospital stay among ICU patients...
  45. ncbi Spread of plasmids containing the bla(VIM-1) and bla(CTX-M) genes and the qnr determinant in Enterobacter cloacae, Klebsiella pneumoniae and Klebsiella oxytoca isolates
    Elisenda Miro
    Servei de Microbiologia, Hospital de Sant Pau, Barcelona, Spain
    J Antimicrob Chemother 65:661-5. 2010
    ....
  46. ncbi [GEIPC-SEIMC and GTEI-SEMICYUC recommendations for antibiotic treatment of gram positive coccal infections in the critical patient]
    P M Olaechea Astigarraga
    Servicio de Medicina Intensiva, Hospital de Galdakao, Bo de Labeaga s n, 48960 Galdakao, Vizcaya, Spain
    Med Intensiva 31:294-317. 2007
    ....
  47. ncbi Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin
    A Torres
    Institut Clinic de Pneumologia i Cirurgia Toracica, Servei de Pneumologia, UVIR, Universitat de Barcelona, IDIBAPS, Barcelona, Spain
    Thorax 55:1033-9. 2000
    ..A prospective multicentre study was undertaken to compare the efficacy of intravenous ciprofloxacin or imipenem in the treatment of severe nosocomial pneumonia requiring mechanical ventilation...
  48. ncbi [Use of antibiotics for the treatment of multiresistant gram positive cocci infections in critical patients]
    O Rodriguez Colomo
    Servicio de Medicina Intensiva, Hospital Clinico Universitario, Valencia, Espana
    Med Intensiva 32:263-71. 2008
    ..This study has been designed to know the use of these antibiotics (ATB) in Intensive Care Units (ICUs)...
  49. ncbi Management of antimicrobial use in the intensive care unit
    Francisco Alvarez-Lerma
    Service of Intensive Care Medicine, Parc de Salut Mar, Universitat Autonoma de Barcelona, Barcelona, Spain
    Drugs 72:447-70. 2012
    ..Finally, pharmacoeconomic aspects should be considered for the choice of appropriate antimicrobials in the care of critically ill patients...
  50. ncbi [Predictive factors for pneumonia in adults infected with the new pandemic A (H1H1) influenza virus]
    Elisabet Lerma Chippirraz
    Servicio de Medicina Interna Enfermedades Infecciosas, Hospital del Mar, Barcelona, Spain
    Rev Esp Quimioter 24:204-8. 2011
    ..The objective of our study was to identify the predictive risk factors of pneumonia in patients with the new A (H1N1) influenza virus infection...
  51. ncbi Factors associated with adherence to guidelines for the use of tigecycline in a tertiary care hospital
    S Grau
    Hospital Universitari del Mar, Autonomous University of Barcelona, Spain
    J Chemother 22:339-44. 2010
    ..971; P=0.001). Adherence to tigecycline protocol could be improved by focusing on protocols for community-acquired infections, mainly skin and soft tissue infections...
  52. ncbi Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections
    M Montero
    Dept of Internal Medicine and Infectious Diseases, Hospital del Mar, Autonomous University of Barcelona, Barcelona, Spain
    Infection 37:461-5. 2009
    ..To describe the clinical and microbiological outcomes of patients infected with multidrug-resistant Pseudomonas aeruginosa (MDRP) treated with colistin (colistimethate sodium) and the adverse events observed with this treatment...
  53. ncbi [Lung aspergillosis. Role of the corticoids as associated risk factor in the patient with chronic bronchitis]
    J M Garces Jarque
    Comisión de Infecciones, Hospital del Mar, Instituto Municipal de Asistencia Sanitaria, Barcelona
    Rev Clin Esp 203:472-4. 2003
    ..Description of a situation of incidence increase of bronchial secretions with positive cultures for Aspergillus fumigatus, and analysis of the related risk factors in the invasive aspergillosis...
  54. ncbi [Pharmacoeconomics of infection in the intensive care unit]
    S Grau
    Servicio de Farmacia, Hospital del Mar, Barcelona, Spain
    Rev Esp Quimioter 21:26-34. 2008
    ....
  55. ncbi Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial
    F Alvarez-Lerma
    Intensive Care Unit, Hospital del Mar, Autonomous University of Barcelona, Passeig Maritim 25 29, 08003 Barcelona, Spain
    Intensive Care Med 27:493-502. 2001
    ....
  56. ncbi Management of antimicrobial use in the intensive care unit
    F Alvarez-Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain
    Drugs 61:763-75. 2001
    ..Although a series of general strategies to reduce the presence of multiresistant pathogens have been proposed, the implementation of these recommendations in ICUs requires the cooperation of a member of the intensive care team...
  57. ncbi [Efficacy of monotherapy by meropenem in ventilator-associated pneumonia]
    F Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital del Mar, Paseo Maritimo 25 29, 08003 Barcelona, Spain
    Antibiot Khimioter 46:42-52. 2001
    ..3%) in the ceftazidime/amikacin group. The results of this study confirm that monotherapy with meropenem is well tolerated and provides superior efficacy to the conventional combination of ceftazidime and amikacin in combating VAP...
  58. ncbi Severe community-acquired pneumonia
    Francisco Alvarez-Lerma
    Service de Medicina Intensiva, Hospital del Mar, , Barcelona, Spain
    Curr Opin Crit Care 10:369-74. 2004
    ..A definitive beneficial effect of early administration of antimicrobials or the knowledge of the etiology of pneumonia on the clinical course of the disease has not been demonstrated...
  59. ncbi [Cefotaxime, twenty years later. Observational study in critically ill patients]
    F Alvarez-Lerma
    Hospital del Mar, Barcelona
    Enferm Infecc Microbiol Clin 19:211-8. 2001
    ..It is mostly used on an empirical basis and associated with other antibiotics. Clinical and microbiological efficiency is high whereas adverse effects related to its use have been scarce...
  60. ncbi [Pandemic influenza A (H1N1)v in the intensive care unit: what have we learned?]
    Alejandro Rodriguez
    Servicio de Medicina Intensiva, IISPV, CIBER Enfermedades Respiratorias, Hospital Universitario Joan XXIII, Tarragona, Espana
    Arch Bronconeumol 46:24-31. 2010
    ..Therefore, early administration of this drug in patients with risk factors or those who, although free from risk factors, show clinical progression, could reduce ICU admissions and mortality...
  61. ncbi [Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006-2010]
    Pedro M Olaechea-Astigarraga
    Servicio de Medicina Intensiva, Hospital Galdakao Usansolo, Vizcaya, Espana
    Enferm Infecc Microbiol Clin 30:435-40. 2012
    ..The use of these agents may have a significant influence on the development of new resistances...
  62. ncbi Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain
    S Grau
    Hospital del Mar, Barcelona, Spain
    J Chemother 17:203-11. 2005
    ..00 and 348.85 Euros, respectively. CONCLUSIONS: LIN was more cost-effective than VAN in the treatment of VAP in Spain, with an additional cost per QALY/LYS gained below the acceptable threshold in Spain of Euros 30,000 for new therapies...
  63. ncbi [An evaluation of blood cultures obtained via a central venous catheter]
    F Alvarez Lerma
    Servicio de Medicina Intensiva, Hospital Universitari del Mar, Barcelona
    Med Clin (Barc) 103:205-8. 1994
    ..The aim of this study was to determine the use of blood samples obtained through central venous catheters (CVC) in the diagnosis of bacteremias in patients admitted to an intensive care unit (ICU)...
  64. ncbi [Summary of the GEIPC-SEIMC and GTEI-SEMICYUC recommendations for the treatment of infections caused by gram positive cocci in critical patients]
    P M Olaechea Astigarraga
    Servicio de Medicina Intensiva, Hospital de Galdakao, Vizcaya, GEIPC, Spain
    Farm Hosp 31:353-69. 2007
    ..The objective is to prepare an antibiotic treatment guide for the most common infections caused by gram positive cocci in critical patients. This guide will help in the decision-making process regarding the care of such patients...
  65. ncbi [Invasive pulmonary aspergillosis in the non-neutropenic critical patient: future challenges]
    P M Olaechea Astigarraga
    Servicio de Medicina Intensiva, Hospital de Galdakao, Vizcaya,
    Med Intensiva 30:386-91. 2006
  66. ncbi [Nosocomial infection indicators]
    M Palomar
    Servicio de Medicina Intensiva, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Espana
    Med Clin (Barc) 131:48-55. 2008
    ..This article presents the indicators obtained in 2007 through both surveillance programs as well as their standards of reference...
  67. ncbi [Community bacteremia ambulatory treated or identified after discharge from the emergency department]
    Roser Terradas
    Servicio de Evaluación y Epidemiología Clínica Hospital del Mar Barcelona España
    Med Clin (Barc) 129:652-4. 2007
    ..The study describes the evolution and the interventions carried out in patients with community bacteremia that were remitted to their home...
  68. ncbi [Nosocomial infection surveillance in critically-ill patients]
    Francisco Alvarez-Lerma
    Enferm Infecc Microbiol Clin 20:103-5. 2002
  69. ncbi Antiseptic chamber-containing hub reduces central venous catheter-related infection: a prospective, randomized study
    Cristóbal León
    Intensive Care Units of Hospital Universitario de Valme, Sevilla, Spain
    Crit Care Med 31:1318-24. 2003
    ....
  70. ncbi Early antibiotic treatment (prophylaxis) of septic complications in severe acute necrotizing pancreatitis: a prospective, randomized, multicenter study comparing two regimens with imipenem-cilastatin
    Enrique Maravi-Poma
    ICU, Servicio Navarro de Salud Osasunbidea, Hospital Virgen del Camino, Irunlarrea 4, 31002, Pamplona, Spain
    Intensive Care Med 29:1974-80. 2003
    ..We compared two imipenem regimens for prevention of septic complications in patients with severe acute necrotizing pancreatitis (ANP)...
  71. ncbi [Surveillance and control of methicillin-resistant Staphylococcus aureus in Spanish hospitals. A GEIH-SEIMC and SEMPSPH consensus document]
    Jesús Rodríguez-Baño
    Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario Virgen Macarena, Sevilla, Espana
    Enferm Infecc Microbiol Clin 26:285-98. 2008
    ..The main measures recommended include appropriate surveillance, hand hygiene, and implementation of active surveillance, contact precautions, and environmental cleaning...
  72. ncbi Pharmacokinetic/pharmacodynamic indices: are we ready to use them in daily practice?
    Santiago Grau
    Expert Rev Anti Infect Ther 5:913-6. 2007
  73. ncbi Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia
    Santiago Grau
    J Antimicrob Chemother 56:440-1. 2005